Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Jaeger

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Cancer Immunology, Immunotherapy : CII|June 18, 2013
Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissueAnna M Sherwood, Ryan O Emerson, Dominique Scherer, et al.
Cancers|April 3, 2021
Predicting the Risk of Metastases by PSMA-PET/CT-Evaluation of 335 Men with Treatment-Naïve Prostate CarcinomaStefan A Koerber, Johannes Boesch, Clemens Kratochwil, et al.
Lung Cancer (Amsterdam, Netherlands)|February 2, 2021
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experienceFlorian Eichhorn, Laura V Klotz, Mark Kriegsmann, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2022
Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trialGeorg Martin Haag, Christoph Springfeld, Barbara Grün, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2023
Impact of <sup>68</sup>Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various CancersStefan A Koerber, Manuel Röhrich, Leon Walkenbach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2018
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric CancerYelena Y Janjigian, Johanna Bendell, Emiliano Calvo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 16, 2020
The Role of <sup>68</sup>Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical ExperienceStefan A Koerber, Fabian Staudinger, Clemens Kratochwil, et al.
Cell Death & Disease|August 19, 2016
Bcl-xL is an oncogenic driver in colorectal cancerAnna-Lena Scherr, Georg Gdynia, Mariam Salou, et al.
Cancer Research|August 18, 2011
Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapyNiels Halama, Sara Michel, Matthias Kloor, et al.
The Lancet. Oncology|October 14, 2016
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trialPadmanee Sharma, Margaret K Callahan, Petri Bono, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Cancer Immunology, Immunotherapy : CII|June 18, 2013
Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissueAnna M Sherwood, Ryan O Emerson, Dominique Scherer, et al.
Cancers|April 3, 2021
Predicting the Risk of Metastases by PSMA-PET/CT-Evaluation of 335 Men with Treatment-Naïve Prostate CarcinomaStefan A Koerber, Johannes Boesch, Clemens Kratochwil, et al.
Lung Cancer (Amsterdam, Netherlands)|February 2, 2021
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experienceFlorian Eichhorn, Laura V Klotz, Mark Kriegsmann, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2022
Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trialGeorg Martin Haag, Christoph Springfeld, Barbara Grün, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2023
Impact of <sup>68</sup>Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various CancersStefan A Koerber, Manuel Röhrich, Leon Walkenbach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2018
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric CancerYelena Y Janjigian, Johanna Bendell, Emiliano Calvo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 16, 2020
The Role of <sup>68</sup>Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical ExperienceStefan A Koerber, Fabian Staudinger, Clemens Kratochwil, et al.
Cell Death & Disease|August 19, 2016
Bcl-xL is an oncogenic driver in colorectal cancerAnna-Lena Scherr, Georg Gdynia, Mariam Salou, et al.
Cancer Research|August 18, 2011
Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapyNiels Halama, Sara Michel, Matthias Kloor, et al.
The Lancet. Oncology|October 14, 2016
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trialPadmanee Sharma, Margaret K Callahan, Petri Bono, et al.
Pageof 6